42 followers
RT @FrontImmunol: New Research: Safety and Preliminary Efficacy of a Novel Host-Modulatory Therapy for Reducing Gingival Inflammation: Back…
RT @FrontImmunol: New Research: Safety and Preliminary Efficacy of a Novel Host-Modulatory Therapy for Reducing Gingival Inflammation: Back…
New Research: Safety and Preliminary Efficacy of a Novel Host-Modulatory Therapy for Reducing Gingival Inflammation: Background Periodontal disease is among the sixth most common inflammatory diseases worldwide with high risk to promote… https://t.co/bDpfg